ST Elevations in the Era of COVID-19

Charlie Joseph Sang 3rd; Brittain Heindl; Gregory Von Mering; Brigitta Brott; Robert S Kopf; Indranee Rajapreyar

doi:10.1155/2020/8845627

ST Elevations in the Era of COVID-19

Case Rep Cardiol. 2020 Aug 6:2020:8845627. doi: 10.1155/2020/8845627. eCollection 2020.

Authors

Charlie Joseph Sang 3rd¹, Brittain Heindl², Gregory Von Mering³, Brigitta Brott³, Robert S Kopf⁴, Indranee Rajapreyar⁵

Affiliations

¹ Internal Medicine-Pediatrics Residency Program, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
² Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
³ Section of Interventional Cardiology, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
⁴ Division of Pulmonary, Allergy, And Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
⁵ Section of Heart Failure and Transplantation Cardiology, Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Abstract

Myocardial injury, represented by elevated cardiac enzymes, has been associated with increased morbidity and mortality in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections. Coronavirus disease 2019 (COVID-19) has created unique challenges in approaching patients with acute ST-segment changes. We describe two distinct cases of ST elevation on electrocardiogram occurring in patients with COVID-19 and review important diagnostic and management considerations for the front-line clinician.

Publication types

Case Reports